Investing.com -- Eli Lilly and Company announced additional positive results today from pivotal Phase 3 trials of its investigational weight loss drug, retatrutide. The data, presented at the American Diabetes Association Scientific Sessions, positions the triple hormone receptor agonist as a potential next-generation successor to current dual-agonist therapies like tirzepatide.

In the 80-week TRIUMPH-1 trial evaluating adults with obesity, participants taking a 12 mg dose of retatrutide lost an average of 70.3 pounds, representing a 28.3% reduction in body weight. Crucially, 65.3% of those on the highest dose achieved a body mass index below 30, meaning they no longer met the clinical criteria for obesity.

Beyond sheer weight reduction, the master trial demonstrated significant improvements across common obesity-related conditions through nested basket studies. For patients suffering from joint complications, retatrutide reduced knee osteoarthritis pain by up to 73.1%, while also lowering the severity of moderate-to-severe obstructive sleep apnea by 60.6%.

Simultaneously published in The Lancet, the 40-week TRANSCEND-T2D-1 trial showed that the therapy is equally potent for adults managing type 2 diabetes. Patients on the triple agonist achieved average blood sugar reductions of up to 2.0%, with nearly half of the participants reaching normal glycemic levels alongside a 16.8% reduction in body weight.

"In TRIUMPH-1 and TRANSCEND-T2D-1, treatment with retatrutide resulted in substantial weight reduction together with clinically meaningful improvements in glycemia, knee osteoarthritis pain, and obstructive sleep apnea, with many individuals reaching what are classified as healthy-range weight and normal blood sugar levels," said Dr. Ania Jastreboff, lead investigator and Director of the Yale Obesity Research Center. "These findings demonstrate what may be possible when we treat obesity and impact overall health, and what this could mean for people living with obesity and its related complications."

The therapeutic breadth of the single molecule extended into cardiovascular health, lowering triglycerides by up to 41.0% and systolic blood pressure by up to 12.3 mmHg. However, the trial data noted standard class-wide side effects, primarily gastrointestinal issues like nausea and diarrhea, which led to an 11.3% discontinuation rate at the highest dosage.

"Across TRIUMPH-1 and TRANSCEND-T2D-1, retatrutide delivered substantial weight loss, meaningful A1C reduction, and improvements in knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea, a breadth and magnitude of outcomes that's striking to see with a single therapy," said Kenneth Custer, executive vice president at Lilly Cardiometabolic Health. "By addressing weight, glycemia and obesity-related complications together, these results highlight retatrutide's potential across the cardiometabolic spectrum and reinforce our commitment to delivering options that meet patients' needs and preferences."

Lilly's latest clinical victory arrives amid an intense pipeline race in a weight-management market projected to exceed $100 billion by the 2030s. At the same conference, competitor Pfizer Inc. presented positive Phase 2b data for its own investigational weight-management candidate, berobenatide, which delivered a 15.9% weight loss at 32 weeks.